US Stock MarketDetailed Quotes
ACGN Aceragen
- 0.385
- 0.0000.00%
Close Aug 22 16:00 ET
3.24MMarket Cap-43P/E (TTM)
0.000High0.000Low0Volume0.000Open0.385Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)8.42MShares1.87752wk High0.14P/B1.33MFloat Cap0.36052wk Low--Dividend TTM3.46MShs Float46920.000Historical High--Div YieldTTM0.00%Amplitude0.360Historical Low--Avg Price1Lot Size
About Aceragen Company
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Company Profile
SymbolACGN
Company NameAceragen
CEOMr. John C. Taylor
MarketNASDAQ
Employees26
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Websitehttps://www.aceragen.com
Company Executives
- Name
- Position
- Salary
- John C. Taylor
- Chief Financial Officer, Chief Executive Officer, President and Director
- 221.19K
- Daniel Salain
- Chief Operating Officer
- --
- Andy Jordan
- Chief Strategy Officer
- --
- Carl N. Kraus
- Chief Medical Officer
- --
- Vincent J. Milano
- Chairman of the Board
- 1.43M
- Ronald Wooten H.C.A.
- Independent Director
- 11.88K
- Dr. Maxine Gowen,PhD
- Independent Director
- 66.24K
- Dr. Cristina Csimma, Pharm.D.
- Independent Director
- 60.12K
- Michael R. Dougherty
- Independent Director
- 89.43K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg